Payment overview · 2025
General Payments
$4,672.20
204 reported records · 33 companies
Healthcare provider profile · identity verified
Michael Klufas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CUMBERLAND, RI · NPI 1205822277
Verified facts
What the public records show
CMS Open Payments records show Michael Klufas, MD received $4,672.20 in general payments during 2025 across 204 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 9.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Ingrezza, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1089 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1089 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $433.59 | 9.3% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $423.86 | 9.1% | 20 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $406.88 | 8.7% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $406.12 | 8.7% | 18 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $360.04 | 7.7% | 21 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $343.61 | 7.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $328.48 | 7.0% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $277.43 | 5.9% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $248.74 | 5.3% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $198.88 | 4.3% | 17 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $171.18 | 3.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.67 | 3.2% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $134.96 | 2.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.07 | 2.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.49 | 2.3% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.60 | 1.9% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.10 | 1.3% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $46.62 | 1.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.87 | 1.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.36 | 0.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.58 | 0.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.73 | 0.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $33.39 | 0.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.12 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.50 | 0.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.18 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.03 | 0.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.83 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.45 | 0.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.47 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.94 | 0.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.29 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.14 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,672.20 | 204 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $433.59 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $406.88 | 22 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $343.61 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $290.50 | 18 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $248.74 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $242.45 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $215.47 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $202.74 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $198.88 | 17 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $187.75 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $171.18 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $148.03 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $148.03 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $148.03 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $140.73 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.24 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.76 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.07 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $105.49 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $94.03 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.70 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.76 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $69.54 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $66.43 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $59.10 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.20 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $49.36 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.48 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.69 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $6.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1089 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 315 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1089 | 108 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
267 | 29 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1089 | 108 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2134 | 389 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1335 | 183 |
| Furosemide | Furosemide | 1296 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 1236 | 206 |
| Eliquis | Apixaban | 1089 | 108 |
| Trazodone Hcl | Trazodone Hcl | 1061 | 164 |
| Lisinopril | Lisinopril | 1028 | 197 |
| Gabapentin | Gabapentin | 855 | 130 |
| Metformin Hcl | Metformin Hcl | 778 | 133 |
| Losartan Potassium | Losartan Potassium | 773 | 146 |
| Sertraline Hcl | Sertraline Hcl | 756 | 96 |
| Metoprolol Tartrate | Metoprolol Tartrate | 683 | 127 |
| Omeprazole | Omeprazole | 648 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 612 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 612 | 110 |
| Mirtazapine | Mirtazapine | 603 | 87 |
| Quetiapine Fumarate | Quetiapine Fumarate | 575 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 382 | 59 |
| Simvastatin | Simvastatin | 369 | 68 |
| Lorazepam | Lorazepam | 354 | 70 |
| Jardiance | Empagliflozin | 315 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 308 | 37 |
| Risperidone | Risperidone | 299 | 33 |
| Clonazepam | Clonazepam | 294 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 88 |
| Xarelto | Rivaroxaban | 280 | 27 |
| Olanzapine | Olanzapine | 270 | 39 |
| Trulicity | Dulaglutide | 267 | 29 |
| Warfarin Sodium | Warfarin Sodium | 262 | 20 |
| Alprazolam | Alprazolam | 255 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 49 |
| Potassium Chloride | Potassium Chloride | 251 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 245 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 55 |
| Divalproex Sodium | Divalproex Sodium | 238 | 23 |
| Levetiracetam | Levetiracetam | 236 | 39 |
| Donepezil Hcl | Donepezil Hcl | 235 | 34 |
| Famotidine | Famotidine | 235 | 41 |
| Buspirone Hcl | Buspirone Hcl | 231 | 39 |
| Ibuprofen | Ibuprofen | 229 | 59 |
| Glipizide | Glipizide | 210 | 37 |
| Clozapine | Clozapine | 208 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 207 | 40 |
| Tramadol Hcl | Tramadol Hcl | 207 | 33 |
| Allopurinol | Allopurinol | 205 | 43 |
| Atenolol | Atenolol | 203 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 191 | 24 |
| Meloxicam | Meloxicam | 190 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 178 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 174 | 27 |
| Myrbetriq | Mirabegron | 171 | 21 |
| Spironolactone | Spironolactone | 167 | 32 |
| Ozempic | Semaglutide | 163 | 27 |
| Montelukast Sodium | Montelukast Sodium | 156 | 30 |
| Aripiprazole | Aripiprazole | 155 | 24 |
| Memantine Hcl | Memantine Hcl | 152 | 16 |
| Finasteride | Finasteride | 147 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 42 |
| Carvedilol | Carvedilol | 137 | 22 |
| Incruse Ellipta | Umeclidinium Bromide | 136 | 13 |
| Baclofen | Baclofen | 129 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 13 |
| Azithromycin | Azithromycin | 126 | 92 |
| Benztropine Mesylate | Benztropine Mesylate | 125 | 12 |
| Alendronate Sodium | Alendronate Sodium | 124 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 26 |
| Latanoprost | Latanoprost | 123 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 24 |
| Cephalexin | Cephalexin | 121 | 72 |
| Prednisone | Prednisone | 118 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 51 |
| Lovastatin | Lovastatin | 115 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 114 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 114 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 106 | 22 |
| Amoxicillin | Amoxicillin | 105 | 61 |
| Ezetimibe | Ezetimibe | 105 | 16 |
| Clonidine Hcl | Clonidine Hcl | 97 | suppressed |
| Bupropion Xl | Bupropion Hcl | 94 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 52 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 53 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 91 | 12 |
| Glipizide Er | Glipizide | 90 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 14 |
| Lactulose | Lactulose | 89 | 14 |
| Lamotrigine | Lamotrigine | 86 | 11 |
| Lithium Carbonate | Lithium Carbonate | 86 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 86 | 17 |
| Januvia | Sitagliptin Phosphate | 85 | suppressed |
| Pregabalin | Pregabalin | 85 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 13 |
| Bumetanide | Bumetanide | 81 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 76 | suppressed |
| Tradjenta | Linagliptin | 75 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 72 | 21 |
| Lidocaine | Lidocaine | 70 | 17 |
| Fenofibrate | Fenofibrate | 68 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 66 | 21 |
| Haloperidol | Haloperidol | 65 | suppressed |
| Ketoconazole | Ketoconazole | 65 | 21 |
| Admelog Solostar | Insulin Lispro | 64 | suppressed |
| Nystatin | Nystatin | 63 | 39 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 30 |
| Perphenazine | Perphenazine | 60 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 34 |
| Naproxen | Naproxen | 59 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 57 | suppressed |
| Permethrin | Permethrin | 57 | 48 |
| Fenofibrate | Fenofibrate,micronized | 56 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 56 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 56 | 46 |
| Clotrimazole | Clotrimazole | 54 | 19 |
| Labetalol Hcl | Labetalol Hcl | 54 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 53 | suppressed |
| Colchicine | Colchicine | 53 | suppressed |
| Digoxin | Digoxin | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Ingrezza | Valbenazine Tosylate | 52 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 52 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Anastrozole | Anastrozole | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 45 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 44 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Erythromycin | Erythromycin Base | 43 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | 14 |
| Topiramate | Topiramate | 43 | suppressed |
| Brilinta | Ticagrelor | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 37 |
| Levofloxacin | Levofloxacin | 39 | 26 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Paliperidone Er | Paliperidone | 39 | suppressed |
| Premarin | Estrogens, Conjugated | 39 | suppressed |
| Ramelteon | Ramelteon | 39 | 11 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Ssd | Silver Sulfadiazine | 38 | 19 |
| Valsartan | Valsartan | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 11 |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 32 | suppressed |
| Restasis | Cyclosporine | 32 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 14 |
| Methocarbamol | Methocarbamol | 31 | 12 |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 29 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 12 |
| Fluconazole | Fluconazole | 28 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Letrozole | Letrozole | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 26 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Travoprost | Travoprost | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 24 | suppressed |
| Epinephrine | Epinephrine | 23 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 12 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Clozapine Odt | Clozapine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con M15 | Potassium Chloride | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluorometholone | Fluorometholone | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 11 | suppressed |
| Lunesta | Eszopiclone | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,672.20 · 204 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, AMVUTTRA, AUSTEDO XR, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, INGREZZA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, M-M-R II, MOUNJARO, NURTEC ODT, NUZYRA, ONPATTRO, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, VYNDAMAX, VYNDAQEL, WATCHMAN Access System, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND, ZORYVE | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error